AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for trastuzumab deruxtecan

 TOKYO and XIAMEN, August 17th, 2026 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic (CDx) for trastuzumab deruxtecan in Japan for patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 mutations.  Read the full story here:

JointRelease_HER2_TDXd_approval_20260813_v2 1.pdf

Download PDF • 321KB